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Abstract
The diabetic foot syndrome (DFS) is among chronic complications of diabetes mellitus; it can affect individuals 
with both type 1 and type 2 diabetes. Diabetic patients have up to a 25% lifetime risk of developing DFS, 
which is both a medical and social problem. Several studies have indicated that, apart from pharmacother-
apy and modern active wound dressings, physical medicine also has a role in prevention and management of 
diabetic foot ulcers. The paper presents physical medicine interventions most recognized in the conservative 
management of DFS.
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Introduction
The United Nations Organization recognized dia-
betes, a non-infectious disease, as an epidemic of the 
21st century [1]. In 2012, diabetes was diagnosed in 371 
million people worldwide, and it has been estimated the 
number will increase to 552 million in 2030. In Poland 
diabetes affects 3 million people, 1 million of whom are 
undiagnosed [2]. The diabetic foot syndrome (DFS) is 
among chronic complications of diabetes mellitus; it can 
affect individuals with both type 1 and type 2 diabetes. 
Diabetic patients have up to a 25% lifetime risk of 
developing DFS [3]. 
The diabetic foot syndrome is characterized by the 
presence of infection and/or ulcer, and/or deep tissue de-
struction as a result of underlying neuropathy and different 
severity ischaemia from peripheral vascular disease [4]. 
DFS involves lesions to blood vessels, nerves, skin 
and bones. The key factors implicated in the develop-
ment of foot ulceration are diabetic neuropathy, macro- 
and microangiopathy, foot deformity, microinjuries 
and infection [5]. 
The most devastating complication of DFS is lower 
limb amputation frequently causing disability. It is esti-
mated that 5% to 15% of patients with foot ulcers will 
require an amputation, with major lower limb amputa-
tions accounting for 50% of these amputations. Over 
50% of the amputees will undergo another amputation 
within 5 years, of whom 50% will not survive the next 
5 years [6]. 
In the years 2009–2012, the rate of major nontrau-
matic lower limb amputations has increased from 9.71 
± 1.92 to 11.96 ± 1.88 per 100,000 Polish population. 
It should also be emphasized that, in that time period, 
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every other major nontraumatic amputation in Poland 
was performed in diabetic patients [7]. 
Hence, DFS is both a medical and social problem. 
Several studies have indicated that, apart from phar-
macotherapy and modern active wound dressings, 
physical medicine also has a role in prevention and 
management of diabetic foot ulcers. The paper presents 
physical medicine interventions most recognized in the 
conservative management of DFS.
 Magnetic field (magnetotherapy  
and magnetostimulation) 
Magnetotherapy and magnetostimulation are physi-
cal medicine therapies based on electromagnetic 
induction consisting of the production of an electro-
motive force in a conductor exposed to a time vary-
ing magnetic field. Depending on the magnetic field 
strength (magnitude), two types of intervention can 
be distinguished, i.e., magnetotherapy (over 100 µT) 
and magnetostimulation (below 100 µT). According 
to the criteria of physical medicine, the magnetic field 
used for magnetic therapy has a frequency below 100 
Hz with induction of 0.1–30 mT, while electromagnetic 
fields of magnetostimulation have a frequency range 
of 1–3000 Hz and magnetic flux density between 1 pT 
and 100 µT [8]. 
At the cellular level, magnetic fields act to acceler-
ate electrolyte exchange between the cell and its sur-
roundings, increase mitotic activity, have antimutagenic 
effects, increase enzyme activity and ATP and DNA 
synthesis. At the tissue level, magnetic fields beneficially 
affect peripheral and microcirculation, enhance angio-
genesis and improve the function as well as irritability 
of nerve fibres [9]. Irrespective of electromagnetic field 
effect on human tissues, it has been used to enhance cell 
respiration, vasodilation, angiogenesis, soft tissue regen-
eration; it also exhibits anti-inflammatory, anti-oedema-
tous and analgetic actions in the treatment of diabetic 
foot [10]. Magnetic field does not exert noticeable 
adverse effects. Contraindications include pregnancy, 
neoplastic disease and active tuberculosis [11].
Several researchers [12, 13] demonstrated benefi-
cial effects of pulsed electromagnetic fields on wound 
healing in streptozotocin-induced diabetic rats; also, 
wound tensile strength was greater in animals exposed 
to extremely low frequency pulsed electromagnetic 
field which was associated with a local increase in my-
ofibroblasts. Cultured medium from human umbilical 
vein endothelial cells exposed to pulsed electromag-
netic fields exhibited a noticeable increase in FGF-2 
expression. Local application of the medium to skin 
flaps created on streptozocin-induced diabetic mice 
facilitated wound healing and increased its tensile 
strength. Pulsed electromagnetic fields were also found 
to prevent ischaemia-associated necrosis [14].
A study on Wistar rats [15] with streptozoto-
cin-induced diabetes mellitus revealed that repetitive 
pulsed magnetic field (50 Hz, 5 mT) ameliorated 
the diabetes-induced macroangiopathy. Diabetic rats 
treated with pulsed magnetic field showed an increase 
in thoracic aorta relaxation response to acetylcholine 
and reduced contraction response to phenylephrine 
compared to the diabetic but non-exposure group. 
Diabetic neuropathy is a complication which is 
far more difficult for pre-clinical studies due to the 
need for endpoint selection. A study on adult male 
Sprague-Dawley rats with streptozotocin-induced di-
abetes [16] exposed to 15 Hz pulsed electromagnetic 
field demonstrated increased hind paw withdrawal 
threshold to mechanical and thermal stimuli, lesser 
extent of demyelination and axon enlargement and 
less vascular endothelial growth factor (VEGF) immu-
nostaining intensity compared to the diabetes mellitus 
with sham pulsed magnetic field exposure group. Thus, 
it can be concluded that pulsed magnetic field prevents 
the progression of diabetic neuropathy. 
The effects of pulsed electromagnetic field were also 
studied in diabetic patients. Kwan et al. [17] exposed 
patients with diabetic foot ulcers to pulsed electromag-
netic field (12 Hz; 1.2 mT) and revealed an increase in 
peripheral microcirculation velocity and wound healing 
acceleration compared with the control group. 
Musaev et al. [18] demonstrated beneficial effects of 
pulsed electromagnetic field (10 Hz) in the initial stages 
of diabetic polyneuropathy as well as in patients with 
diabetes mellitus of less than 10 years’ duration; the 
conductivity of peripheral sensory and motor nerves 
was found to have improved.
In a study conducted in 16 American academic and 
clinical centres [19], low-frequency pulsed electromagnetic 
fields were applied onto the feet of patients with stage 2 
or 3 diabetic polyneuropathy. Patients exposed to pulsed 
electromagnetic field exhibited a trend toward reductions in 
diabetic polyneuropathy symptoms on the Patient’s Global 
Impression of Change scale (PGIC) as well as increased epi-
dermal nerve fibre density which was significantly correlated 
with decreases in analogue pain scores.
Wróbel et al. [20], on the other hand, concluded that 
genuine magnetic field exposure had no advantage over 
sham exposure in reducing pain intensity, improving 
quality of life and decreasing sleep disturbances and 
glycated haemoglobin concentrations.
Hyperbaric oxygen therapy
Hyperbaric oxygen therapy (HBOT) is providing 
the body with 100% oxygen delivered at 2.5 times 
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normal atmospheric pressure. The most important 
benefits include increased oxygenation of hypoxic and 
ischaemic tissues, wound healing acceleration, signifi-
cant reduction of oedema, circulation improvement, 
immunity enhancement as well as bacteriocidal and 
bacteriostatic actions. HBOT also enhances white 
blood cell proteolysis of necrotic tissues, fibroblast 
proliferation, bone remodelling along with osteoblastic 
and osteoclastic activity, angiogenesis, epithelial cell 
migration and collagen deposition and cross-linking. 
Hyperbaric therapy is given in a total body chamber. The 
only absolute contraindication of hyperbaric oxygen 
therapy is an untreated pneumothorax. The relative 
contraindications include upper respiratory infections, 
history of thoracic or ear surgery, emphysema with CO2 
retention, pregnancy, claustrophobia, low threshold for 
seizures and bleomycin therapy [21, 22].
An analysis of seven randomized clinical trials con-
ducted in the years 1992–2013 to assess the value of 
HBOT in a total of 376 patients demonstrated some 
effectiveness of the therapy in promoting the healing of 
diabetic foot ulcers and preventing amputations [23]. 
However, clinical studies on the use of hyperbaric 
oxygen in conservative treatment of diabetic foot have 
not yet resulted in a clinical application at the practi-
tioner level. Huang et al. recommend HBOT in patients 
with Wagner Grade ≥ 3 diabetic foot ulcers who had 
recently undergone surgical debridement as well as 
in Wagner Grade ≥ 3 diabetic foot ulcers that do not 
heal within 30 days of surgical debridement; in these 
patients hyperbaric oxygen seems to promote wound 
healing and prevent amputation. There is no adequate 
evidence to justify the use of HBOT in patients with 
Grade ≤ 2 diabetic foot ulcers [24].
A retrospective study of Akgul et al. [25] revealed 
that ischaemic heart disease, stroke, proliferative and 
nonproliferative retinopathy had an adverse effect on 
HBOT results in patients with DFS. Average scores 
of peripheral arterial disease at femoral level affected 
HBOT results more negatively than single arterial 
scores and average scores at popliteal and pedal levels. 
However, the diabetic lower extremity wound response 
to HBO2 therapy was unaffected by glycaemic control 
prior to treatment. After 20 HBOT sessions carried 
out over 30 days, no differences were noted between 
patients with HbA1C < 7.5% and ≥ 7.5% regarding ulcer 
surface area and depth. Hence, HBOT should not be 
delayed due to suboptimal blood glucose control [26]. 
Exposure of murine diabetic wounds to hyperbaric 
oxygen [27] stabilized and activated the hypoxia-induc-
ible factor 1 (HIF-1), which is known to promote cell 
proliferation in a healing wound. 
HBOT has also been noted to reduce the risk of QTc 
interval prolongation which protects against life-threaten - 
ing arrhythmias. After a 2-year follow-up, QTc time 
was significantly shorter in the HBOT group, whose 
members had received 40 treatment sessions at 2.5 
ATA, compared with the placebo group [28].
Fife et al. [29] reported outcomes in a large num-
ber of patients who had received hyperbaric oxygen 
therapy for diabetic low-extremity ulcers. The authors 
concluded that hyperbaric oxygen treatment should 
be an important adjunctive therapy to heal lower-ex-
tremity lesions, especially those with a Wagner grade 
of 3 or higher. 
Ozone therapy
Ozone exhibits bactericidal, virucidal and fungicidal 
properties; it promotes granulation, enhances wound 
epidermis formation, local tissue oxygen saturation and 
eliminates odour associated with chronic wounds. The 
efficacy of ozone therapy stems from the fact of most 
microorganisms being sensitive to ozone exposure. 
Medical ozone is actually a mixture of 5% maximum 
ozone and 95% oxygen. Contraindications to ozone 
therapy include untreated hyperthyroidism, recent 
myocardial infarction, uncontrolled hypertension and 
alcohol intoxication [30]. 
Martinez-Sanchez et al. [31] compared the thera-
peutic efficacy of ozone and antibiotic therapy in the 
treatment of diabetic foot syndrome. Ozone treatment 
improved glycaemic control, reduced oxidative stress 
and promoted the healing process thus reducing the 
number of amputations compared with the control 
group on antibiotic therapy. No side effects were 
observed.
In another study [32], patients with diabetes melli-
tus complicated by lower limb angiopathy and diabetic 
retinopathy were evaluated for the efficacy of external, 
systemic (intravenous or rectal) or combined tech-
niques of ozone-oxygen administration. The external 
administration proved superior in the treatment of 
lower limb ulceration whereas the systemic and com-
bined methods produced better effects with respect to 
retinopathy and biochemical parameters. 
OXYBARIA S 
OXYBARIA S is a novel portable and reusable sys-
tem for simultaneous hyperbaric oxygen and ozone 
therapy of chronic wounds. The combination of the 
two methods improves local tissue oxygenation thereby 
accelerating chronic wound healing. Bactericidal action 
promotes wound cleanliness, which also has a beneficial 
effect on the healing process [33].
The method was developed by professor Aleksan-
der Sieroń, Department of Internal Diseases, Angiology 
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and Physical Medicine, Medical University of Silesia. 
It won a Grand Prix award at the 63rd International 
Exhibition on Inventions, Research and New Technol-
ogies BRUSSELS INNOVA in 2014. The applied ozone 
concentration of 20 mg/cm3 is reached after 5 minutes 
of the generator’s work. The system is also equipped 
with an ozone neutralizer. The recommended ozone 
flow rate ranges from 5–8 l/minute. The device is 
self-contained and portable which makes it easy to use 
not only in hospitals but also family doctors’ offices or 
in the patient’s home. Hence, the cost of treatment 
is reduced [33]. A double-blind, randomized clinical 
trial conducted in diabetic patients with a Wagner 
classification stage 2 or 3 ulcer or a stage 4 ulcer after 
surgical debridement, all treated for at least 12 weeks 
with oxygen-ozone combination, revealed a significantly 
higher rate of complete wound closure compared to 
sham-treated participants [34]. Among ozone-oxygen 
subjects with wound size £ 5 cm, the rate of total 
wound closure was 100%. 
The efficacy of oxygen-ozone treatment of diabetic 
foot ulcers was also confirmed by Zhang et al. [35]. 
Wound size was significantly reduced in the oxy-
gen-ozone group (plus standard therapy) compared 
with the control (standard therapy only). Following the 
treatment, local expression of growth factors involved 
in wound healing, i.e., vascular endothelial growth fac-
tor (VEGF), transforming growth factor beta (TGF-b) 
and platelet-derived growth factor (PDGF) was signif-
icantly higher in the oxygen-ozone group.
Laser therapy 
Laser emits light through the amplification based on 
the stimulated emission of electromagnetic radiation. 
Lasers are divided into groups according to different 
criteria, e.g., the state of matter of the active medium 
(solid, liquid, gas, plasma), spectral range of the laser 
wavelength (visible spectrum, ultra-violet spectrum, 
infra-red spectrum) or energy level (high, medium and 
low energy). High power lasers are used in surgical 
dermatology, eye surgery and neurosurgery. Physical 
medicine typically uses lower energy lasers that do not 
have a thermal effect on tissue; however, there have 
been more and more reports on the application of high 
energy lasers. Upon reaching a tissue, laser radiation is 
reflected or absorbed and dissipated. Effective absorb-
ers of the light include melanin, aromatic amino acids 
(tyrosine, tryptophan), water, blood and haemoglobin. 
Collagen of the basal layer controls light dissipation 
(especially that of shortwave light). Depending on the 
angle of light incidence and surface structure, 40–50% 
of radiation may be reflected. While planning laser ther-
apy, it should be remembered that effective penetration 
depth in the tissue is proportional to wavelength, i.e., 
infrared light has the deepest tissue penetration. Bio-
logical effects of laser therapy are not caused by body 
temperature elevation, since the latter only increases 
by 0.1–1°C. It is the interaction between the tissue 
and electromagnetic radiation that results in oxygen 
intake, regeneration processes and cell proliferation 
enhancement, vessel dilation, anti-inflammatory and 
anti-oedematous effects, a decrease in the conductive 
properties of nociceptive afferents and a change in the 
activity of serotonergic synapses due to an increase in 
beta-endorphin levels. There are no absolute contrain-
dications to laser therapy but caution should be taken 
in pregnant women, patients with active neoplastic 
disease, severe infections, electronic implants and those 
on photosensitizing medications [8, 36]. 
Laser wavelength of 632.8 nm (visible range) has 
been found to produce the most beneficial effects with 
respect to the migration, viability and proliferation of 
diabetic wounded and unwounded human skin fibro-
blasts WS1) [37]. However, a choice of irradiation dose 
still remains a problem. In an in vitro study on wounded 
human skin fibroblasts, heliumneon laser irradiation in 
a single dose of 5 J/cm2 and two or three doses of 2.5 J/cm2 
had a stimulatory effect on wounded fibroblasts with an 
increase in cell migration and cell proliferation. Multiple 
exposure to 16 J/cm2 inhibited cell proliferation (healing) 
and caused damage to wounded cells [38].
Pal et al. [39] found that the total energy dose had 
greater influence on cellular proliferation and the ki-
netics of reactive oxygen species generation than did 
laser intensity.
Low-intensity laser irradiation also increased col-
lagen type I content, cell migration, proliferation and 
viability in diabetic wounded fibroblasts [40]. 
The efficacy of laser therapy in the treatment of dia-
betic foot syndrome was also studied in clinical settings. 
Kajagar et al. [41] studied patients with type 2 
diabetes mellitus and foot ulcers; they observed that 
a group with conventional and low level laser therapy 
had a significant reduction in ulcer area compared with 
patients on conventional therapy only. A double-blind 
clinical trial [42] also confirmed accelerated reduction of 
ulcer size and larger number of patients with complete 
healing in the group who received laser therapy. Heli-
umneon and infra-red laser therapy of diabetes-related 
skin lesions improved blood flow parameters compared 
with patients who had only received conventional 
treatment [43].
Negative Pressure Wound Therapy
Negative Pressure Wound Therapy (NPWT) is 
a therapeutic technique consisting of the application 
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of negative pressure (125 mm Hg) to the wound bed. 
NPWT accelerates wound healing by stimulating the 
formation of granulation tissue as well as fibroblast and 
endothelial cells proliferation, elimination of excess exu-
date from wound surface, reduction of periwound oede-
ma, improvement of blood supply to wound bed, mainte-
nance of adequate wound humidity and reduction of the 
microorganism burden on the wound surface [44, 45]. 
The therapy is particularly useful in patients with excess 
wound exudate but should not be applied in those with 
high risk for prolonged bleeding (e.g., taking anticoag-
ulant medications) [5]. 
In patients with type 2 diabetes mellitus, NPWT 
significantly reduced the size and/or accelerated healing 
of ulcers in patients with mixed and neuropathic origin 
diabetic foot syndrome [46]. Sajid et al. [47] observed 
that NPWT using assisted wound closure was more 
effective than advanced moist wound therapy in the 
management of diabetic foot ulcers.
Conclusions
There has been an increasing number of Polish and 
international reports on the efficacy of physical med-
icine interventions, including electromagnetic fields, 
hyperbaric oxygen therapy, low energy lasers or nega-
tive pressure wound therapy, which all have been used 
as adjuncts to conventional therapies for diabetic foot 
ulcers. Thanks to modern technology, therapy devices 
are now smaller, lighter, more user-friendly and cheaper. 
Consequently, the therapies have become more availa-
ble, not only in specialist hospital departments but also 
at outpatient clinics or even in the patient’s home. It 
should be emphasized that the interventions appear to 
be safe for use with very few contraindications. 
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